Next results · Q4 2026Projected
Mar 4, after the close
Thu, Mar 4, 2027in 107 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 26 – Mar 12
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $6.72M
- Revenue, change from a year earlier: Q3 2026 +94.3%, Q2 2026 +25.3%, Q1 2026 +128.0%, Q4 2025 +66.8%
- Net income
- -$8.17M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 −47.2%, Q3 2025 n/m
Results day
Typical moveA typical move of 9.9% either way
Up after 2 of 8, down after 6.
The stock’s move from the last close before each release to the first close after it, over the last 8 releases. Largest: −29.1% after Q4 2025.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Thursday
- 5 of its last 8
- Session
- after the close
- After quarter end
- 7 to 64 days
- 10-Q filed
- 37 to 44 days
- over its last 6
- 10-K filed
- 64 to 66 days
- over its last 2
Based on 2 prior 10-K filings.
Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR